ddI — a Good Start, but Still Phase I

Publisher Website
Google Scholar
Abstract
Ever since the human immunodeficiency virus (HIV) was identified as the causative agent of the acquired immunodeficiency syndrome (AIDS), investigators have mounted an intensive effort to develop antiviral drugs with activity against HIV. In early 1987, zidovudine was approved for use in adults with AIDS or symptomatic HIV infection and fewer than 200 CD4+ T lymphocytes per cubic millimeter. In early 1990, zidovudine was further approved for use in asymptomatic HIV-infected persons with fewer than 500 CD4+ T lymphocytes per cubic millimeter. At present, zidovudine is the only drug approved for use as an anti-HIV agent. Since its approval by . . .